US Stock MarketDetailed Quotes
GILD Gilead Sciences
- 91.165
- +0.675+0.75%
Trading Nov 26 13:32 ET
113.62BMarket Cap1012.94P/E (TTM)
91.310High89.630Low1.41MVolume90.340Open90.490Pre Close126.96MTurnover0.11%Turnover Ratio20.26P/E (Static)1.25BShares98.90052wk High6.15P/B113.39BFloat Cap60.75052wk Low3.06Dividend TTM1.24BShs Float98.900Historical High3.36%Div YieldTTM1.86%Amplitude0.405Historical Low90.291Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Gilead Sciences Stock Forum
low attention stock, just another day!
Crypto: $Coinbase (COIN.US)$ $GEMINI GROUP GLOBAL CORP (GMNI.US)$ $Riot Platforms (RIOT.US)$
Financials: $JPMorgan (JPM.US)$ $Morgan Stanley (MS.US)$ $Wells Fargo & Co (WFC.US)$
Traditional Energy: $Exxon Mobil (XOM.US)$ $Chevron (CVX.US)$ $ConocoPhillips (COP.US)$
Biotechnology: $Amgen (AMGN.US)$ $Gilead Sciences (GILD.US)$ $ROCHE HOLDING AG (RHHBY.US)$ $Biogen (BIIB.US)$ $Regeneron Pharmaceuticals (REGN.US)$
...
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
I really regret sold my LLY at 240, and REGN at 450. Then they never come back.
Just past the 4 pm ET close, the $S&P 500 Index (.SPX.US)$ climbed 2.30%, the $Dow Jones Industrial Average (.DJI.US)$ climbed 1.76%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 2.87%.
MACRO
Thursday in macroeconomics, initial jobless claims came in at 233k, lower than 250k l...
$Humacyte (HUMA.US)$ : 🤔
⇨ Human Acellular Vessel (HAV)™
‣ Vascular Trauma
‣ PDUFA: 8/10/24 (BLA)
🗓️ Last Week’s AdCom & PDUFAs:
$Zevra Therapeutics (ZVRA.US)$ : Favorable AdCom 👍
🗳️ 11-5 votes in favor
⇨ Arimoclomol
‣ Niemann-Pick disease type C
‣ AdCom: 8/2/24 (NDA)
$Adaptimmune Therapeutics (ADAP.US)$ : Approved 🎉
⇨ TECELRA (afamitresgene autoleucel)
‣ Synovial sarcoma
‣ PDUFA: 8/4/24 (BLA)
$GlaxoSmithKline (GSK.US)$ : Approved 🎉
⇨ Jemperli
‣ Endometria...
your own platform is most valuable and made 2 Billion for the company. You just let people go…
No comment yet